RenovoRx(RNXT) - 2025 Q2 - Quarterly Results

Exhibit 99.1 RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review Revenue from RenovoCath device totaled over $400,000 for the Second Quarter 2025 MOUNTAIN VIEW, Calif. – August 14, 2025 – RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing ...